STOCK TITAN
  1. Home
  2. Sec-filings
  3. CABA
  4. [SCHEDULE 13G/A] Cabaletta Bio, Inc. SEC Filing

[SCHEDULE 13G/A] Cabaletta Bio, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock CABA logo
Cabaletta Bio, Inc.

NASDAQ:CABA

CABA Rankings

#6813 Ranked by Market Cap
N/A Ranked by Dividends

CABA Latest News

Jun 11, 2025
Cabaletta Bio Announces Pricing of Public Offering of Securities
Jun 11, 2025
Cabaletta Bio Announces Proposed Public Offering of Securities
Jun 11, 2025
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress
May 29, 2025
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
May 15, 2025
Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts

CABA Latest SEC Filings

Jun 20, 2025
[SCHEDULE 13G] Cabaletta Bio, Inc. SEC Filing

CABA Stock Data

153.80M
88.43M
3.1%
79.62%
13.83%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
PHILADELPHIA